Bristol Myers Squibb (BMY)

[chmcnfunds]

Jefferies Expects a Bristol-Myers Squibb Bounce

Another drug stock Jefferies weighed in on was BMY, with the brokerage firm setting a price target of $66. This represents 15.6% upside to BMY's Wednesday close at $57.12, and territory not seen since before an August bear gap. Nevertheless, Bristol-Myers Squibb Co shares are trading slightly lower ahead of the bell, on track to add to their roughly 14% year-to-date deficit. Should upbeat analysts begin to change their tune, the stock could see additional technical trouble. Currently, eight of 13 brokerages maintain a "buy" or better rating, leaving the door wide open for downgrades.

http://www.schaeffersresearch.com/content/news/2017/03/09/johnson-johnson-merck-bristol-myers-squibb-upgraded?utm_source=SM&utm_medium=Link&utm_campaign=Twitter

BMY